What question did this study set out to answer?

The study aims to determine how GLP-1 and dual agonists influence the incidence of physician-reported sleep apnea.

February 12, 2026

Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: A real-world study

Key Points

The study aims to determine how GLP-1 and dual agonists influence the incidence of physician-reported sleep apnea.
Conducted a retrospective cohort study using TriNetX Global Health Research Network data.
Included adult patients with obesity and/or type 2 diabetes without prior GLP-1 or dual agonist prescriptions.
Matched initiators of GLP-1/dual agonists to a reference cohort using propensity score matching.
Identified new cases of sleep apnea using validated ICD-10 codes.
GLP-1/dual agonists were linked to a 54% lower incidence of physician-reported sleep apnea (HR: 0.46).
Individually, liraglutide, dulaglutide, semaglutide, and tirzepatide all showed significant reductions in incidence.
Exploratory analysis indicated a 79% lower incidence of positive airway pressure reports in the treatment group.

Abstract

Abstract Rationale Previous studies have shown that glucagon-like peptide-1 (GLP-1) agonists and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists (tirzepatide) reduced severity of sleep apnea. However, whether these medications impact incidence of new cases of physician-reported sleep apnea (PRSA) is unknown. Objective To determine the potential impact of GLP-1 and dual agonists on the incidence of sleep apnea reports and to explore potential treatment consequences for this sleep-disordered breathing. Methods We conducted a retrospective cohort study using the TriNetX Global Health Research Network through anonymized electronic medical records. We identified adult patients with obesity and/or type 2 diabetes mellitus never prescribed GLP-1 or dual agonists therapy (reference arm) and those new initiators of these medications. The index event (June 2022) was chosen to coincide with the launching of tirzepatide in the market. We excluded patients with type 1 diabetes, previous diagnosis of PRSA, under previous use of GLP-1/dual agonists, orlistat, phentermine/topiramate, bupropion/naltrexone as well as patients with previous bariatric surgery. Initiators were matched to the reference cohort using propensity score matching in a 1:1 ratio for age, sex, ethnicity, body mass index and menopause. We used a validated algorithm to identify PRSA using International Classification of Diseases 10th edition codes. Results The follow-up time was 1044 days. After propensity score matching, a total of 1,253,188 patients were included in the reference arm and GLP-1/dual agonists’ comparison. Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR: 0.46; 95% CI: 0.45–0.49). Individually, all drugs were able to reach this outcome as compared to the reference arm: liraglutide (HR: 0.64, 95% CI: 0.51–0.80); dulaglutide (HR: 0.32, 95% CI: 0.28–0.36); semaglutide (HR: 0.57, 95% CI: 0.54–0.61); tirzepatide (HR: 0.74, 95% CI: 0.67–0.92). Exploratory analysis revealed a 79% lower incidence of positive airway pressure reports in the GLP-1/dual agonists group as compared to controls. Conclusions GLP-1/dual agonists reduced the incidence of new cases of PRSA in patients with obesity and/or type 2 diabetes.

Bookmark

Cite This Study

Prado et al. (Tue,) studied this question.

synapsesocial.com/papers/698d6e1a5be6419ac0d5379e https://doi.org/https://doi.org/10.1093/annalsats/aaoaf071

Bookmark